Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 8/20 | 0.68 |
| ▸ | MMP14 | P50281 | 2/20 | 0.68 |
| ▸ | MMP13 | P45452 | 3/20 | 0.67 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.67 |
| ▸ | MMP7 | P09237 | 1/20 | 0.67 |
| ▸ | MMP12 | P39900 | 1/20 | 0.67 |
| ▸ | NPC1 | O15118 | 7/20 | 0.61 |
| ▸ | RAB9A | P51151 | 7/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | CLK1 | P49759 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.58 |
| ▸ | RELA | Q04206 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3618865 | 0.86 | MMP2 (0.67) | MMP2MMP14MMP13ADAMTS4MMP7 | |
| SCHEMBL3618866 | 0.86 | MMP2 (0.67) | MMP2MMP14MMP13ADAMTS4MMP7 | |
| SCHEMBL3618261 | 0.83 | MMP2 (0.78) | MMP2MMP14MMP13ADAMTS4MMP7 | |
| SCHEMBL3618034 | 0.82 | MMP2 (0.82) | MMP2MMP14MMP13ADAMTS4MMP7 | |
| SCHEMBL27593743 | 0.81 | NPC1 (0.72) | MMP2MMP14MMP13ADAMTS4MMP7 | |
| SCHEMBL3617526 | 0.81 | MMP2 (0.71) | MMP2MMP14MMP13ADAMTS4MMP7 | |
| SCHEMBL3615340 | 0.81 | MMP2 (1.00) | MMP2MMP14MMP13ADAMTS4MMP7 | |
| SCHEMBL3614041 | 0.80 | MMP2 (0.69) | MMP2MMP14MMP13ADAMTS4MMP7 | |
| SCHEMBL5094144 | 0.80 | MMP2 (0.69) | MMP2MMP14MMP13ADAMTS4MMP7 | |
| SCHEMBL2382350 | 0.80 | MMP2 (1.00) | MMP2MMP14MMP13ADAMTS4MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1692124-B1 | BIARYL SULFONAMIDES AS MMP INHIBITORS | WYETH CORP (US) | 2008-10-15 | — | — | EP | claimed |
| US-7420001-B2 | Biaryl sulfonamides and methods for using same | WYETH (US) | 2008-09-02 | — | — | US | claimed |
| US-20050143422-A1 | Biaryl sulfonamides and methods for using same | WYETH (US) | 2005-06-30 | — | — | US | claimed |
| US-20100137298-A1 | Biaryl Sulfonamides and Methods for Using Same | WYETH (US) | 2010-06-03 | — | — | US | disclosed |
| EP-1692124-B1 | BIARYL SULFONAMIDES AS MMP INHIBITORS | WYETH CORP (US) | 2008-10-15 | — | — | EP | disclosed |
| US-7420001-B2 | Biaryl sulfonamides and methods for using same | WYETH (US) | 2008-09-02 | — | — | US | disclosed |
| US-20050143422-A1 | Biaryl sulfonamides and methods for using same | WYETH (US) | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137298-A1 | Biaryl Sulfonamides and Methods for Using Same | STS, MMP3, AADAC | MMP2 5/4885MMP14 19/4885MMP13 13/4885 |
| US-20050143422-A1 | Biaryl sulfonamides and methods for using same | STS, MMP3, AADAC | MMP2 5/4885MMP14 19/4885MMP13 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.